These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36453216)

  • 21. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
    Boursier J; Canivet CM; Costentin C; Lannes A; Delamarre A; Sturm N; Le Bail B; Michalak S; Oberti F; Hilleret MN; Irles-Depé M; Fouchard I; Hermabessiere P; Barthelon J; Calès P; Cariou B; de Ledinghen V; Roux M
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1243-1251.e12. PubMed ID: 35288342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
    PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prevalence of Advanced Liver Fibrosis Among Patients With Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia.
    Lee XH; Nor LM; Ang CS; Yeow TP; Lim SL
    J ASEAN Fed Endocr Soc; 2023; 38(1):52-61. PubMed ID: 37252406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.
    Lee DH; Sung SU; Lee YK; Lim IH; Jang H; Joo SK; Park JH; Chang MS; So YH; Kim W;
    Aliment Pharmacol Ther; 2022 Apr; 55(8):994-1007. PubMed ID: 35005800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
    Udompap P; Therneau TM; Canning RE; Benson JT; Allen AM
    Hepatology; 2023 Mar; 77(3):931-941. PubMed ID: 35989502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
    Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
    BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.
    Serra-Burriel M; Graupera I; Torán P; Thiele M; Roulot D; Wai-Sun Wong V; Neil Guha I; Fabrellas N; Arslanow A; Expósito C; Hernández R; Lai-Hung Wong G; Harman D; Darwish Murad S; Krag A; Pera G; Angeli P; Galle P; Aithal GP; Caballeria L; Castera L; Ginès P; Lammert F;
    J Hepatol; 2019 Dec; 71(6):1141-1151. PubMed ID: 31470067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population.
    Singh J; Ibrahim B; Jackson NJ; Khalil H; Valenzuela J; Yanny B; Saab S
    Transl Gastroenterol Hepatol; 2024; 9():16. PubMed ID: 38716213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.
    Kosick HM; Keyrouz A; Adeyi O; Sebastiani G; Patel K
    Dig Dis Sci; 2021 Nov; 66(11):4046-4057. PubMed ID: 33389416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
    Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
    JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
    Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
    Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Detection of Fibrotic Nonalcoholic Fatty Liver Disease in Community-Based Referrals.
    Piao C; Arteaga EJ; Chen S; Guo A; Macdonald ST; Sarkar S
    Metab Syndr Relat Disord; 2023 Nov; 21(9):475-478. PubMed ID: 37756226
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Dincses E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case-finding strategies in non-alcoholic fatty liver disease.
    Boursier J; Tsochatzis EA
    JHEP Rep; 2021 Apr; 3(2):100219. PubMed ID: 33659890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.